Novartis says Dendreon plant deal will drive CAR processing
Novartis says the acquisition of Dendreon’s Provenge plant was an investment in its activated cellular immunotherapy programme.
Novartis says the acquisition of Dendreon’s Provenge plant was an investment in its activated cellular immunotherapy programme.
A US advocacy group says poor HHS oversight of an ongoing type-1 diabetes study could undermine rules designed to protect children in trials.
Winning US FDA approval for omega-3 API suppliers like BASF and Chemport is a key milestone for Amarin in 2013 according to CEO Joe Zakrzewski.
Icon claims its collaboration with electronic Health record (EHR) specialist Cerner will help drug and device makers streamline data collection.